PE20121552A1 - Anticuerpos monoclonales anti cea humanizados de afinidad madura - Google Patents
Anticuerpos monoclonales anti cea humanizados de afinidad maduraInfo
- Publication number
- PE20121552A1 PE20121552A1 PE2012000266A PE2012000266A PE20121552A1 PE 20121552 A1 PE20121552 A1 PE 20121552A1 PE 2012000266 A PE2012000266 A PE 2012000266A PE 2012000266 A PE2012000266 A PE 2012000266A PE 20121552 A1 PE20121552 A1 PE 20121552A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- monoclonal antibodies
- humanized anti
- heavy chain
- light chain
- Prior art date
Links
- 230000002494 anti-cea effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE UNION A ANTIGENO (ABM) TAL COMO UN ANTICUERPO QUE COMPRENDE UN DOMINIO DE UNION A ANTIGENO QUE SE UNE AL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA) UNIDO A MEMBRANA, EL CUAL COMPRENDE A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE i) UNA CDR1 DE CADENA PESADA QUE CONSISTE EN LAS SEC ID Nº 1, 2, 3, 5, 6, 7, 8, 9, 10 O 12, ii) UNA CDR2 DE CADENA PESADA QUE CONSISTE EN LAS SEC ID Nº 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, ENTRE OTROS, iii) UNA CDR3 DE CADENA PESADA QUE CONSISTE EN LAS SEC ID Nº 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 O 35; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE i) UNA CDR1 DE CADENA LIGERA QUE CONSISTE EN LAS SEC ID Nº 36, 37, 38, 39, 40, 41, 42, 43, 44 O 45, ii) UNA CDR2 DE CADENA LIGERA QUE CONSISTE EN LAS SEC ID Nº 46, 47, 48, 49, 50, 51, 52, 53, 54 O 55, iii) UNA CDR3 DE CADENA LIGERA QUE CONSISTE EN LA SEC ID Nº 56. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23850509P | 2009-08-31 | 2009-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121552A1 true PE20121552A1 (es) | 2012-11-26 |
Family
ID=42985489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000266A PE20121552A1 (es) | 2009-08-31 | 2010-08-27 | Anticuerpos monoclonales anti cea humanizados de afinidad madura |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9068008B2 (es) |
| EP (1) | EP2473532B1 (es) |
| JP (1) | JP5744872B2 (es) |
| KR (1) | KR101528013B1 (es) |
| CN (1) | CN102741293B (es) |
| AR (1) | AR078111A1 (es) |
| AU (1) | AU2010288469A1 (es) |
| BR (1) | BR112012003983A2 (es) |
| CA (1) | CA2770174A1 (es) |
| CL (1) | CL2012000551A1 (es) |
| CO (1) | CO6491105A2 (es) |
| CR (1) | CR20120087A (es) |
| EC (1) | ECSP12011698A (es) |
| IL (1) | IL218038A0 (es) |
| MA (1) | MA33536B1 (es) |
| MX (1) | MX339608B (es) |
| PE (1) | PE20121552A1 (es) |
| RU (1) | RU2570554C2 (es) |
| SG (1) | SG178567A1 (es) |
| TW (1) | TW201121994A (es) |
| WO (1) | WO2011023787A1 (es) |
| ZA (1) | ZA201200954B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
| EP2672999A2 (en) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Improved immunotherapy |
| WO2012117002A1 (en) * | 2011-03-02 | 2012-09-07 | Roche Glycart Ag | Cea antibodies |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2686327T3 (es) | 2011-08-23 | 2018-10-17 | Roche Glycart Ag | Moléculas de unión a antígeno biespecíficas |
| AU2012298537B2 (en) | 2011-08-23 | 2017-08-10 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| GB201213858D0 (en) | 2012-08-03 | 2012-09-19 | Mab Design Ltd | Method |
| SG11201407580YA (en) | 2012-08-07 | 2014-12-30 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
| BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| CN110845618A (zh) | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| JP2016512421A (ja) * | 2013-02-26 | 2016-04-28 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| CR20160534A (es) | 2014-04-27 | 2017-04-25 | Ccam Biotherapeutics Ltd | Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1) |
| CR20170032A (es) | 2014-08-04 | 2017-04-04 | Hoffmann La Roche | Moleculas biespecíficas de unión a antígeno activadoras de células t |
| HUE049650T2 (hu) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Közös könnyûláncok és alkalmazási eljárások |
| CA2960929A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| KR20240024318A (ko) | 2014-11-20 | 2024-02-23 | 에프. 호프만-라 로슈 아게 | T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
| BR112018003984A2 (pt) | 2015-12-09 | 2018-09-25 | Hoffmann La Roche | anticorpos |
| CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| DK3433280T5 (da) | 2016-03-22 | 2024-09-16 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| CN118772288A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| CN113906053B (zh) * | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| WO2020260329A1 (en) | 2019-06-26 | 2020-12-30 | F. Hoffmann-La Roche Ag | Fusion of an antibody binding cea and 4-1bbl |
| CN110862456B (zh) * | 2019-09-23 | 2021-04-09 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| CN110713539B (zh) * | 2019-09-23 | 2021-04-16 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
| MX2023002017A (es) | 2020-08-20 | 2023-04-28 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para ceacam. |
| MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
| IL306111A (en) | 2021-04-30 | 2023-11-01 | Hoffmann La Roche | Dosage for combined treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody and anti-CD79B antibody for antiretroviral drugs |
| IL314523A (en) * | 2022-01-27 | 2024-09-01 | Janssen Biotech Inc | Improved protein compositions |
| WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
| TW202506733A (zh) | 2023-06-12 | 2025-02-16 | 美商安進公司 | 淋巴毒素β受體促效劑結合蛋白 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| BR9207126A (pt) * | 1992-05-07 | 1995-08-29 | Sterling Winthrop Inc | Imunorreagente radioativo de marcação,composição formadora de imagem,composição terapêutica,processo para a formação de imagem diagnóstica em um sítio em um paciente e para tratar sítios de doença em um paciente,e,composição de matéria |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2417415C (en) | 2000-07-31 | 2012-10-09 | Biolex, Inc. | Expression of biologically active polypeptides in duckweed |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1467615B2 (en) | 2001-12-27 | 2017-03-22 | GlycoFi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| CA2819867A1 (en) | 2002-03-19 | 2003-09-25 | Stichting Dienst Landbouwkundig Onderzoek | Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants |
| EP1502603A4 (en) * | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| JPWO2003085119A1 (ja) * | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| US7300655B2 (en) * | 2002-08-01 | 2007-11-27 | Immunomedics, Inc. | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof |
| AU2003270152A1 (en) | 2002-09-12 | 2004-04-30 | Greenovation Biotech Gmbh | Protein production method |
| JP4559358B2 (ja) | 2002-12-20 | 2010-10-06 | グリーンオベーション バイオテク ゲーエムベーハー | コケ細胞における異種グリコシル化タンパク質の産生 |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| JP4889493B2 (ja) * | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| WO2012117002A1 (en) * | 2011-03-02 | 2012-09-07 | Roche Glycart Ag | Cea antibodies |
-
2010
- 2010-08-27 RU RU2012112340/10A patent/RU2570554C2/ru active
- 2010-08-27 SG SG2012013306A patent/SG178567A1/en unknown
- 2010-08-27 BR BR112012003983-0A patent/BR112012003983A2/pt not_active Application Discontinuation
- 2010-08-27 CA CA2770174A patent/CA2770174A1/en not_active Abandoned
- 2010-08-27 AU AU2010288469A patent/AU2010288469A1/en not_active Abandoned
- 2010-08-27 KR KR1020127008265A patent/KR101528013B1/ko not_active Expired - Fee Related
- 2010-08-27 JP JP2012526072A patent/JP5744872B2/ja not_active Expired - Fee Related
- 2010-08-27 CN CN201080048622.1A patent/CN102741293B/zh not_active Expired - Fee Related
- 2010-08-27 PE PE2012000266A patent/PE20121552A1/es not_active Application Discontinuation
- 2010-08-27 EP EP10745651.9A patent/EP2473532B1/en active Active
- 2010-08-27 MX MX2012002461A patent/MX339608B/es active IP Right Grant
- 2010-08-27 WO PCT/EP2010/062527 patent/WO2011023787A1/en active Application Filing
- 2010-08-30 AR ARP100103166A patent/AR078111A1/es not_active Application Discontinuation
- 2010-08-30 TW TW099129130A patent/TW201121994A/zh unknown
- 2010-08-31 US US12/872,908 patent/US9068008B2/en active Active
-
2012
- 2012-01-30 CO CO12014021A patent/CO6491105A2/es not_active Application Discontinuation
- 2012-02-08 ZA ZA2012/00954A patent/ZA201200954B/en unknown
- 2012-02-09 IL IL218038A patent/IL218038A0/en unknown
- 2012-02-20 CR CR20120087A patent/CR20120087A/es unknown
- 2012-02-27 MA MA34650A patent/MA33536B1/fr unknown
- 2012-02-28 EC ECSP12011698 patent/ECSP12011698A/es unknown
- 2012-02-29 CL CL2012000551A patent/CL2012000551A1/es unknown
-
2015
- 2015-05-26 US US14/721,795 patent/US20160075795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012003983A2 (pt) | 2021-09-14 |
| CN102741293A (zh) | 2012-10-17 |
| RU2570554C2 (ru) | 2015-12-10 |
| CN102741293B (zh) | 2015-04-01 |
| KR20120060874A (ko) | 2012-06-12 |
| EP2473532B1 (en) | 2017-06-21 |
| US20160075795A1 (en) | 2016-03-17 |
| MA33536B1 (fr) | 2012-08-01 |
| AR078111A1 (es) | 2011-10-12 |
| US9068008B2 (en) | 2015-06-30 |
| MX339608B (es) | 2016-05-31 |
| WO2011023787A1 (en) | 2011-03-03 |
| US20110104148A1 (en) | 2011-05-05 |
| KR101528013B1 (ko) | 2015-06-16 |
| CR20120087A (es) | 2012-03-22 |
| ECSP12011698A (es) | 2012-03-30 |
| SG178567A1 (en) | 2012-04-27 |
| RU2012112340A (ru) | 2013-10-10 |
| CO6491105A2 (es) | 2012-07-31 |
| TW201121994A (en) | 2011-07-01 |
| MX2012002461A (es) | 2012-03-14 |
| CA2770174A1 (en) | 2011-03-03 |
| JP2013502913A (ja) | 2013-01-31 |
| AU2010288469A1 (en) | 2012-03-01 |
| EP2473532A1 (en) | 2012-07-11 |
| HK1176951A1 (en) | 2013-08-09 |
| ZA201200954B (en) | 2014-07-30 |
| CL2012000551A1 (es) | 2012-10-12 |
| IL218038A0 (en) | 2012-04-30 |
| JP5744872B2 (ja) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20140814A1 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| PE20120014A1 (es) | Anticuerpos humanos de alta afinidad contra pcsk9 | |
| CY1117922T1 (el) | Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
| PE20120415A1 (es) | Anticuerpos anti-igf | |
| ATE477276T1 (de) | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen | |
| AR091605A1 (es) | Proteinas de union anti-mesotelina | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |